What View Point Medical does

View Point Medical is a Carlsbad, California-based medical device company founded in 2016 that develops tissue marker and imaging systems for tumor localization in cancer care, with an initial focus on breast cancer. Its core product, the OneMark Detection Imaging System, is an ultrasound-based imaging platform purpose-built to detect visually enhanced OneMark Tissue Markers placed at the time of biopsy, enabling surgeons to localize and resect marked lesions without preoperative wire or radioactive localization procedures. The FDA-cleared system (2024) combines a capital equipment sale with a consumable tissue-marker stream, addressing re-excision rates and workflow inefficiencies in breast cancer surgery.

The company sells directly to U.S. hospitals and surgical centers via an enterprise field sales motion, operating a trial waitlist for early adoption targeting breast cancer surgeons and interventional radiology departments. Through April 2026, View Point operated as a privately held venture-backed entity, raising approximately $61.45 million across three SEC Form D exempt securities offerings in 2022, 2023, and 2024. In April 2026, Merit Medical Systems acquired View Point Medical for approximately $140 million ($90 million cash plus two $25 million deferred payments), making it a wholly-owned subsidiary and embedding the OneMark platform within Merit's therapeutic oncology distribution and regulatory infrastructure.

Name

View Point Medical

Legal name

View Point Medical, Inc.

Website

https://viewpointmed.com

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

1–10 employees

Short description

View Point Medical develops ultrasound-based tissue marker and imaging systems for tumor localization in cancer care, initially targeting breast cancer surgery for U.S. hospitals and surgical centers. Now a wholly-owned subsidiary of Merit Medical Systems following its April 2026 acquisition.

Ownership category

akta.pro rank

Product category

Surgical Oncology Localization Devices

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mammography & Breast Imaging Systems (HLAHABAF)

akta.pro secondary industry

Portable, Mobile & Point-of-Care Imaging Systems (HLAHABAL)

Keywords

• Tumor localization devices
• Breast cancer imaging
• Surgical tissue markers
• Cancer resection systems
• Medical imaging hardware

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. OneMark Detection Imaging System Sales: Sale of the OneMark Detection Imaging System to hospitals and surgical centers for tumor localization procedures.
2. OneMark Tissue Markers: Sale of disposable tissue markers used during tumor localization procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

View Point Medical develops and sells the OneMark Detection Imaging System and OneMark Tissue Markers for breast and soft tissue tumor localization. The ultrasound-based imaging system enables surgeons to detect visually enhanced markers placed at biopsy, streamlining workflow from marker placement to surgical resection. The company's first indication is breast cancer, with additional cancer indications under development.

Product overview

View Point Medical offers a focused portfolio centered on the OneMark Detection Imaging System and OneMark Tissue Markers. The system is a surgeon-centric imaging platform designed for tumor localization, specifically targeting breast cancer initially with potential applications for additional cancer indications. The products work together to enable visual detection of enhanced markers placed during biopsy, streamlining the treatment workflow from placement to resection.

Differentiator

Problem solved

Functional benefit

Products and services

• OneMark Detection Imaging System The first surgeon-centric ultrasound-based imaging system designed for the localization of visually enhanced tissue markers placed at the time of biopsy. Enables surgeons to rapidly detect and visualize marked tissue for simplified treatment workflow and more precise cancer resection. Sold to hospitals, breast cancer centers, and surgical facilities.
• OneMark Tissue Markers FDA-cleared disposable tissue markers used in breast and soft tissue tumor localization procedures, designed to work in conjunction with the OneMark Detection Imaging System. Sold to hospitals and surgical centers performing biopsy and resection.

Quantifiable outcome

• Potential to significantly reduce re-excision rates during tumor removal procedures

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Merit Medical SystemscoreStrategic or Co-development Partner · 1 April 2026Merit Medical Systems acquired View Point Medical through a merger transaction for approximately $140 million (effective April 1, 2026), making View Point a wholly-owned subsidiary. The transaction expanded Merit Medical's therapeutic oncology portfolio with View Point's FDA-cleared OneMark Detection Imaging System and OneMark Tissue Markers for breast and soft tissue tumor localization.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Cianna Medical (Savi Scout): Cianna Medical developed the Savi Scout wire-free radar localization system for breast tumor localization, the closest direct competitor to View Point's OneMark. Now a Merit Medical brand, Savi Scout competes head-to-head with OneMark in the same US hospital channel for wire-free breast lesion localization.
• Endomag: Endomag markets the Magseed magnetic marker and Magtrace lymphatic tracer for wire-free breast tumor localization, competing directly with OneMark Tissue Markers in breast conservation surgery workflows across US and European hospitals.
• Mammotome (Danaher/Leica Biosystems): Mammotome is a leading breast biopsy and tissue marker manufacturer offering biopsy site markers used in conjunction with vacuum-assisted breast biopsy systems. Their biopsy markers are commonly used in the same clinical workflow where OneMark Tissue Markers would be deployed.

Broad incumbents

• Hologic: Hologic is a major women's health medical device company offering mammography systems, breast biopsy guidance, and biopsy markers. As a broad incumbent in breast imaging and intervention, Hologic serves the same hospital breast surgery customers as View Point with a wider portfolio spanning screening, diagnostics, and intervention.
• Becton Dickinson (BD): BD manufactures breast biopsy site markers, ultrasound systems, and a wide range of medical devices used in surgical and interventional settings. Its breast tissue marker portfolio overlaps directly with View Point's disposable marker offering.
• Merit Medical Systems: Merit Medical Systems is the strategic acquirer of View Point Medical (April 2026) and operates a broad portfolio of interventional oncology, peripheral vascular, and breast health products. As View Point's parent company, Merit is the primary commercialization channel and competes with diversified MedTech portfolios across the same hospital accounts.
• Siemens Healthineers: Siemens Healthineers offers mammography, ultrasound, and image-guided biopsy systems widely used in breast imaging suites. As a broad incumbent imaging vendor, Siemens competes with View Point's ultrasound detection approach at the modality level in breast imaging departments.
• GE HealthCare: GE HealthCare manufactures mammography systems, ultrasound platforms, and image-guided intervention tools used in breast cancer diagnosis and treatment. Its installed ultrasound base is a potential integration or replacement pathway relevant to OneMark's detection workflow.

Emerging players

• iCAD: iCAD provides AI-based breast imaging software for mammography and breast tomosynthesis, serving similar radiology customers as View Point's breast localization workflow. Its ProFound AI suite intersects with the diagnostic imaging pathway preceding biopsy and localization.
• Volpara Health (Lunit): Volpara Health, now part of Lunit, provides breast imaging analytics and AI for mammography. As an emerging software-focused player in breast imaging, Volpara serves the same radiology departments evaluating new technologies like OneMark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about View Point Medical